Article
Immunology
Shahram Seyfi, Kayvan Latifi, Parviz Amri Male, Mahmoud Sadeghi Haddad Zavareh, Khadijeh Ezoji, Mousa Mohammadnia-Afrozi
Summary: This study retrospectively evaluated the clinical treatment outcomes of COVID-19 inpatients who received IFN-beta 1-a and IFN-beta 1-b. The results showed no significant difference between the two groups in terms of shortening disease time, clinical improvements, and other outcomes.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Clinical Neurology
Izanne Roos, Emmanuelle Leray, Romain Casey, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Sara Eichau Madueno, Francesco Patti, Gilles Edan, Marc Debouverie, Jean Pelletier, Serkan Ozakbas, Maria Pia Amato, Pierre Clavelou, Pierre Grammond, Cavit Boz, Katherine Buzzard, Olga Skibina, Jonathan Ciron, Oliver Gerlach, Francois Grand'Maison, Jeannette Lechner-Scott, Charles Malpas, Helmut Butzkueven, Sandra Vukusic, Tomas Kalincik, PGCertBiostat, MSBase and OFSEP Study Grp
Summary: High-efficacy therapy is more effective in reducing relapses in patients with active SPMS compared to low-efficacy therapy, but no difference was observed in relapse frequency between the two therapies in patients with inactive SPMS. There was no evidence for a difference in disability progression risk between high- and low-efficacy therapies in treated patients with SPMS.
Article
Clinical Neurology
Izanne Roos, Emmanuelle Leray, Romain Casey, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Sara Eichau Madueno, Francesco Patti, Gilles Edan, Marc Debouverie, Jean Pelletier, Serkan Ozakbas, Maria Pia Amato, Pierre Clavelou, Pierre Grammond, Cavit Boz, Katherine Buzzard, Olga Skibina, Jonathan Ciron, Oliver Gerlach, Francois Grand'Maison, Jeannette Lechner-Scott, Charles Malpas, Helmut Butzkueven, Sandra Vukusic, Tomas Kalincik
Summary: The study found that high-efficacy therapy is more effective in reducing relapse frequency in patients with active SPMS compared to low-efficacy therapy, but no significant difference was observed in patients with inactive SPMS. There was also no difference in disability progression between the two groups of patients.
Article
Surgery
Amelia J. Hessheimer, Ana Magdalena Vargas-Martinez, Marta Trapero-Bertran, Miquel Navasa, Constantino Fondevila
Summary: This study evaluated the cost-effectiveness and utility of posttransplant hepatocellular carcinoma (HCC) surveillance compared to standard follow-up. Although surveillance slightly improves survival and quality of life, it also increases costs and does not appear to be cost-effective in this setting.
Article
Pharmacology & Pharmacy
Dolores Canales Siguero, Carmen Garcia-Munoz, Francisco Martinez de la Torre, Jose Miguel Ferrari Piquero, Miguel Angel Granados Ruiz
Summary: This study described the efficacy and safety of interferon beta-1B treatment in two infants under one year of age with viral myocarditis, showing recovery of cardiac function in both cases after six months. This is the first published series of cases in infants of this age group treated with interferon beta-1B.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
(2021)
Article
Endocrinology & Metabolism
David Tak Wai Lui, Ivan Fan Ngai Hung, Chi Ho Lee, Alan Chun Hong Lee, Anthony Raymond Tam, Polly Pang, Tip Yin Ho, Chloe Yu Yan Cheung, Carol Ho Yi Fong, Chun Yiu Law, Kelvin Kai Wang To, Ching Wan Lam, Wing Sun Chow, Yu Cho Woo, Karen Siu Ling Lam, Kathryn Choon Beng Tan
Summary: Short-term IFN treatment in COVID-19 survivors may lead to modest increases in anti-thyroid antibody titres, as well as a trend of more incident anti-thyroid peroxidase antibody positivity and abnormal thyroid function tests. Further studies are needed to determine the clinical significance of these changes and to guide monitoring practices for IFN-treated individuals.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Immunology
Anthony Raymond Tam, Ricky Ruiqi Zhang, Kwok Cheung Lung, Raymond Liu, Ka Yi Leung, Danlei Liu, Yujing Fan, Lu Lu, Athene Hoi Ying Lam, Tom Wai Hin Chung, Cyril Chik Yan Yip, Jenny Lo, Alan Ka Lun Wu, Rodney Lee, Simon Sin, Pauline Yeung Ng, Wai Ming Chan, Hoi Ping Shum, Wing Wa Yan, Jasper Fuk Woo Chan, Vincent Chi Chung Cheng, Chak Sing Lau, Kelvin Kai-Wang, Kwok Hung Chan, Kwok Yung Yuen, Ivan Fan Ngai Hung
Summary: Combined treatment with interferon beta-1b and remdesivir is more effective than remdesivir alone in the treatment of COVID-19, providing relief for symptoms, reducing viral shedding and hospitalization time, and inducing earlier antibody response in high-risk patients.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Clinical Neurology
Francesco Patti, Javier Nicolas Penaherrera, Lorissa Zieger, Eva-Maria Wicklein
Summary: This study provides observational data on MS patients between 40 and 72 years of age, suggesting that IFNB-1b can be an effective and well-tolerated treatment option in patients of advanced age.
Article
Clinical Neurology
Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Bernard Uitdehaag, Gary Cutter
Summary: The study compared the frequency of progression and improvement events in SPMS trials using data from the placebo arms of two large RCTs. The EDSS showed the highest rates of improvement over time, with the smallest difference between progression and improvement rates, followed by the T25FW and 9HPT. The findings suggest random variation and measurement error in all investigated outcome measures, with the T25FW and 9HPT showing less than the more established outcome measure EDSS.
Article
Plant Sciences
Guan-Ting Erica Chen, Jian You Wang, Muhammad Jamil, Justine Braguy, Salim Al-Babili
Summary: This study provides direct evidence for the formation of SLs from 9-cis-beta-apo-10'-carotenal and explores the use of labeled long-chain apocarotenoids as a promising approach to investigate apocarotenoid metabolism and the genesis of carotenoid-derived growth regulators and signaling molecules.
Article
Pharmacology & Pharmacy
Rui Luo, He Lu, Hengfen Li
Summary: This study conducted a cost-utility analysis of different long-acting injections in patients with schizophrenia in China. The results showed that both PP3M and PP1M are more cost-effective compared to ER in the Chinese healthcare system, and PP3M has notable cost-utility advantages over PP1M.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Biotechnology & Applied Microbiology
J. P. Sevilla, Daria Burnes, Rehab Zakaria El Saie, Hammam Haridy, Matt Wasserman, Sarah Pugh, Johnna Perdrizet, David Bloom
Summary: This study evaluates the return on investment after the introduction of pediatric pneumococcal conjugate vaccines in Egypt from the perspectives of healthcare payers and society. The findings demonstrate that the introduction of PCV13 yields higher benefits compared to no vaccination or vaccination with PCV10.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2022)
Article
Health Care Sciences & Services
Rajabali Daroudi, Mirtaher Mousavi, Marzieh Shirazikhah, Mehdi Alizadeh Zarei, Hamidreza Hendi, Faezeh Joghataei, Ali Darvishi
Summary: This study evaluated the cost-utility of MS multidisciplinary rehabilitation in Iran. The rehabilitation strategy was found to be cost-effective, resulting in higher quality-adjusted life years (QALYs) values. Increasing the time horizon increased the probability of rehabilitation being cost-effective.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
(2023)
Article
Chemistry, Multidisciplinary
Luis F. Gonzalez, Eric Acuna, Gabriel Arellano, Paola Morales, Paula Sotomayor, Felipe Oyarzun-Ampuero, Rodrigo Naves
Summary: A new delivery system of IFN-β nanoparticles via intranasal administration was developed to improve clinical symptoms and control neuroinflammation in an experimental model of multiple sclerosis, showing potential effectiveness, non-invasiveness, and cost-effectiveness as a therapy for MS.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Chemistry, Analytical
Aline Cournut, Paul Moustiez, Yannick Coffinier, Christine Enjalbal, Claudia Bich
Summary: Alzheimer's disease is a major cause of senile dementia and is characterized by the aggregation of neurofibrillary tangles and amyloid plaques in the brain. The A beta 1-42 peptide is considered the primary cause of neurotoxicity due to its insolubility and subsequent aggregation. A beta 1-42 and A beta 1-40 have been identified as relevant biomarkers for AD diagnosis, and SurfaceAssisted Laser Desorption/Ionization Mass Spectrometry (SALDI-MS) was used to monitor the A beta 1-42/A beta 1-40 ratio without prior sample treatment.
Editorial Material
Clinical Neurology
Giovanni Novi, Federico Ivaldi, Elvira Sbragia, Malgorzata Mikulska, Giampaola Pesce, Matilde Inglese, Nicole Kerlero de Rosbo, Antonio Uccelli
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION
(2020)
Article
Dermatology
Florian Kron, Sebastian M. Wingen-Heimann, Julia Jeck, Carlo Lazzaro, Oliver A. Cornely, Christian Thielscher
Summary: Based on the principal-agent theory (PAT), this study analyzed the perspectives of patients, physicians, pharmacists, and hospital managers on the use of ISA, as well as the health economic effects of using ISA from a hospital management perspective. The analysis showed the beneficial role of ISA in healthcare resource utilization, mainly due to a shortened overall length of hospital stay. The study also highlighted the disincentives for hospital managers to use innovative drugs and the need for reducing bureaucratic hurdles in Germany for the extension of effective and innovative antifungal treatment strategies with ISA.
Article
Biophysics
Carlo Lazzaro, Luca Castagna, Francesco Lanza, Daniele Laszlo, Giuseppe Milone, Luca Pierelli, Riccardo Saccardi
Summary: The study compared the cost-effectiveness of using G-CSF alone versus high-dose cyclophosphamide + G-CSF mobilization in Italian multiple myeloma patients eligible for autograft. The findings revealed that G-CSF alone was a more cost-effective option, demonstrating incremental savings and a higher probability of successful apheresis.
BONE MARROW TRANSPLANTATION
(2021)
Article
Neurosciences
Federico Carlini, Federico Ivaldi, Francesca Gualandi, Ursula Boschert, Diego Centonze, Giuseppe Matarese, Marco Salvetti, Nicole Kerlero de Rosbo, Antonio Uccelli
Summary: The study reveals an important relationship between dCK activity and the effect of cladribine on B and T cells, depending on their activation status. Further research is needed to evaluate whether dCK activity could be a suitable predictive biomarker of lymphocyte response to cladribine in the future.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY
(2022)
Letter
Oncology
Carlo Lazzaro
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Immunology
Giovanni Ferrara, Federico Ivaldi, Gianluigi Mancardi, Nicole Kerlero de Rosbo, Antonio Uccelli
Summary: Transplantation of BMC after II transiently ameliorates clinical symptoms of RR-EAE during the early phase of the disease, but co-transplantation with MSC does not have a synergistic effect.
Article
Ophthalmology
Carlo Lazzaro, Cecile van Steen, Stephan Billeit, Heinrich Frauenknecht, Christopher Kallen, Stefan Pfennigsdorf, Ulrich Thelen, Luigi Angelillo
Summary: This study aimed to estimate the cost-utility and economic value of STN1013001, a latanoprost cationic emulsion, compared to other latanoprost formulations in patients with open-angle glaucoma or ocular hypertension and concomitant ocular surface disease in Germany. The results showed that STN1013001 was more cost-effective and produced more quality-adjusted life years (QALYs) compared to latanoprost.
CLINICAL OPHTHALMOLOGY
(2022)
Article
Clinical Neurology
Carlo Lazzaro, Roberto Bergamaschi, Mauro Zaffaroni, Rocco Totaro, Damiano Paolicelli
Summary: This study aimed to compare the costs and quality-adjusted life years (QALYs) of teriflunomide in naïve patients with relapsing-remitting multiple sclerosis (RRMS) and experienced patients previously treated with other disease-modifying therapies in Italy. The results showed that teriflunomide was cost-effective and potentially strongly dominant in naïve RRMS patients from both the healthcare sector and societal viewpoints.
NEUROLOGICAL SCIENCES
(2022)
Article
Ophthalmology
Carlo Lazzaro, Cecile van Steen, Florent Aptel, Cedric Schweitzer, Luigi Angelillo
Summary: This study investigated the cost utility of STN1013001 compared to Latanoprost in patients with OAG/OHT and concomitant OSD in France. The results showed that over a 5-year period, STN1013001 resulted in an incremental 0.35 QALYs gained at an incremental cost of euro7.39 compared to Latanoprost, resulting in an ICUR of euro21.26. Sensitivity analyses confirmed the robustness of the baseline results.
JOURNAL OF OPHTHALMOLOGY
(2022)
Article
Clinical Neurology
Antonio Uccelli, Mark S. Freedman
MULTIPLE SCLEROSIS JOURNAL
(2022)
Editorial Material
Economics
Carlo Lazzaro
EUROPEAN JOURNAL OF HEALTH ECONOMICS
(2023)
Article
Health Care Sciences & Services
Carlo Lazzaro, Cecile van Steen, Giorgio Ghirelli, Matteo Sacchi, Dario Sisto, Maurizio Uva, Luigi Varano, Luigi Angelillo
Summary: This study conducted a cost-utility analysis of STN1013001, an innovative latanoprost cationic emulsion, compared to other latanoprost formulations. The results suggest that STN1013001 is potentially highly cost-effective and dominant in treating open-angle glaucoma/ocular hypertension (OAG/OHT) and ocular surface disease (OSD). Further evidence is needed to assess the cost-effectiveness of collecting information on OAG/OHT utilities and OSD-related disutility. Future real-world cost-utility analyses should also consider the availability of STN1013001 in the Italian market.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
(2023)
Article
Health Care Sciences & Services
Carlo Lazzaro, Nicola Amedeo Mazzanti, Silvia Rossi, Fabio Parazzini
Summary: In Italy, the Italian National Health Service (INHS) has started reimbursing the treatment costs for NMOSD patients with inebilizumab as a second line monotherapy after rituximab use. It is eligible for patients aged 18 or above, who are anti-aquaporin 4 antibody-immunoglobulin G positive and experienced a relapse in the last year or cannot receive rituximab. Other reimbursed drugs for NMOSD treatment in Italy include satralizumab, eculizumab, and off-label use of ocrelizumab, tocilizumab, and immunosuppressants.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
(2023)
Article
Pathology
Carlo Lazzaro, Giovanni Fattore, Massimo Barberis, Fiamma Buttitta, Paola Cassoni, Paolo Graziano, Antonio Marchetti, Stefania Crema, Francesca Dal Pero, Mauro Giulio Papotti
Summary: The objective of this study was to calculate the full cost of diagnostic pathology tests for Non-Small Cell Lung Cancer (NSCLC) in four Italian Pathology Units. Pathologists provided data on NSCLC samples and the necessary healthcare resources. The total cost per NSCLC tissue sample reached 659.77 euros, with the majority being direct costs. The findings can help negotiate new tariffs for NSCLC sample processing with third-party payers.
Article
Clinical Neurology
Alessandro Masala, Ilaria Di Mola, Maria Cellerino, Valentina Pera, Aldo Vagge, Antonio Uccelli, Cordano Christian, Carlo E. Traverso, Michele Iester
Summary: The study utilized EDI-OCT to investigate changes in choroidal thickness in MS patients, revealing a significant increase in CT in patients with a history of ON, along with thinner RNFL.
JOURNAL OF CLINICAL NEUROLOGY
(2022)
